Greg J Elder
Biographic Data
| ID | 8239236 |
|---|---|
| NAME | Greg J Elder |
| GIVEN NAMES | Greg J |
| FAMILY NAME | Elder |
| SIGNATURE | ELDER G J |
| AFFILIATIONS | Newcastle Hospitals - Campus for Ageing and Vitality |
| VERIFIED | No |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 3 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2016 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens
Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médecins Sans Frontières (MSF) sponsored a phase 2b-3 randomised controlled trial (TB-PRACTECAL), which identified a new treatment regimen for drug-resistant TB. We aimed to analyse the costs of undertaking a pivotal clinical trial conducted in relatively low-resource heal…
Recently developed drugs for the treatment of drug-resistant tuberculosis
Two drugs with novel mechanisms of action, the diarylquinoline bedaquiline and the nitroimidazole delamanid—as well as pretomanid from the same class of drugs as delamanid—have recently become available to treat drug-resistant tuberculosis (DR-TB) after many decades of little innovation in the field of DR-TB treatment. Despite evidence of improved efficacy and reduced toxicity of multidrug regimens including the two agents, access to bedaquiline …
Assessing the daily stability of the cortisol awakening response in a controlled environment
The stability of the CAR profile and total cortisol secretion, but not awakening cortisol levels or the magnitude of increase, was demonstrated across two consecutive mornings of measurement in a highly-controlled environment. Awakening cortisol levels, and the magnitude of increase, may be sensitive to differences in daily activities
No prominent works on this page.
Assessing the daily stability of the cortisol awakening response in a controlled environment
The stability of the CAR profile and total cortisol secretion, but not awakening cortisol levels or the magnitude of increase, was demonstrated across two consecutive mornings of measurement in a highly-controlled environment. Awakening cortisol levels, and the magnitude of increase, may be sensitive to differences in daily activities
Recently developed drugs for the treatment of drug-resistant tuberculosis
Two drugs with novel mechanisms of action, the diarylquinoline bedaquiline and the nitroimidazole delamanid—as well as pretomanid from the same class of drugs as delamanid—have recently become available to treat drug-resistant tuberculosis (DR-TB) after many decades of little innovation in the field of DR-TB treatment. Despite evidence of improved efficacy and reduced toxicity of multidrug regimens including the two agents, access to bedaquiline …
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens
Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médecins Sans Frontières (MSF) sponsored a phase 2b-3 randomised controlled trial (TB-PRACTECAL), which identified a new treatment regimen for drug-resistant TB. We aimed to analyse the costs of undertaking a pivotal clinical trial conducted in relatively low-resource heal…
Internal Medicine (3 works) · Medicine (3 works) · Bedaquiline (2 works) · Business (2 works) · Clinical trial (2 works) · Pharmaceutical Economics and Policy (2 works) · Tuberculosis (2 works) · Accounting (1 work) · Biosimilars and Bioanalytical Methods (1 work) · Circadian rhythm (1 work)